DECLARATION OF CONFLICT OF INTEREST Disclosure : None. Independent study founded and performed within the Italian National Healthcare System. Approval by the relevant institutional ethical review boards, written informed consent by participants.
Presenter: Massimo Imazio, MD, FESC
on behalf of the CORP Investigators
Cardiology Dpt. Maria Vittoria Hospital,
ASLTO2, Torino, Italy
RRR=Relative Risk Reduction
*= single-center, open-label RCTs
*COPE- Circulation 2005;112:2012-6;
*CORE- Arch Int Med 2005;165:1987-91
J Cardiovasc Med 2007; 8: 830-4
°aspirin, 800-1000mg (or ibuprofen, 600mg) orally every 8 hours for 7-10 days (1st choice); prednisone, 0.2-0.5 mg/kg/day for 4 weeks (2nd choice), for all gradual tapering; †Colchicine/Placebo: 1.0 mg BID for 1 day then 0.5mg BID for 1 month (Pts >= 70Kg); 0.5 mg BID for 1 day then 0.5mg for 1 month (Pts<70Kg)
No patients lost to follow-up
All patients analysed for outcomes
RRR= 56% 95% CI 27-73; NNT=3
Placebo Colchicine p
†= median (10th to 90th percentile)
Imazio M, et al.
NR= not randomised, ROL= randomised, open label; RRR-relative risk reduction
Imazio M et al. submitted
Following an initial episode of recurrent pericarditis, colchicine, as adjunct to empiric anti-inflammatory therapy, appears to be an in-expensive and safe means
The most important acknowledgement is to the participants in the study and to the physicians, nurses, ethical committees, and administrative staff in hospitals who assisted with its conduct.
Cardiology Dpt, Maria Vittoria Hospital, Torino, Italy (Coordinating Centre; investigators: M. Imazio, D. Forno, S. Ferro, R. Belli), Ospedali Riuniti, Bergamo, Italy (investigators: A. Brucato, S. Maestroni, D. Cumetti), Department of Cardiology, San Maurizio Regional Hospital, Bolzano, Italy (R. Cemin), Ospedale SS Annunziata, Savigliano, Italy (S. Ferrua, A. Bassignana, B. Doronzo).